{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:38Z","timestamp":1793068478188,"version":"4.5.0"},"reference-count":93,"publisher":"Society of Nuclear Medicine","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Nucl. Med.\n                Technol."],"accepted":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.2967\/jnmt.125.270169","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:40:17Z","timestamp":1764855617000},"page":"92S-101S","source":"Crossref","is-referenced-by-count":8,"title":["Challenges and Opportunities in Radioligand Therapy"],"prefix":"10.2967","volume":"53","author":[{"given":"Geoffrey M.","family":"Currie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2025121109350930000_53.Supplement_1.92S.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.119.232462"},{"key":"2025121109350930000_53.Supplement_1.92S.2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jmir.2019.09.005","article-title":"Machine learning and deep learning in medical imaging: intelligent imaging","volume":"50","author":"Currie","year":"2019","journal-title":"J Med Imaging Radiat Sci."},{"key":"2025121109350930000_53.Supplement_1.92S.3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.semnuclmed.2020.08.002","article-title":"Intelligent imaging in nuclear medicine: the principles of artificial intelligence, machine learning and deep learning","volume":"51","author":"Currie","year":"2021","journal-title":"Semin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/jmrs.836","article-title":"Molecular theranostics: principles, challenges and controversies","volume":"72","author":"Currie","year":"2025","journal-title":"J Med Radiat Sci."},{"key":"2025121109350930000_53.Supplement_1.92S.5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1053\/j.semnuclmed.2025.01.007","article-title":"Sharpening the blade of precision theranostics","volume":"55","author":"Currie","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.6","first-page":"17","article-title":"Reinventing pharma: the theranostic revolution","volume":"2","author":"Funkhouser","year":"2002","journal-title":"Curr Drug Discov."},{"key":"2025121109350930000_53.Supplement_1.92S.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.220665"},{"key":"2025121109350930000_53.Supplement_1.92S.8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00259-013-2609-2","article-title":"Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine","volume":"41","author":"Verburg","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.9","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.7150\/thno.57004","article-title":"Smart magnetic resonance imaging-based theranostics for cancer","volume":"11","author":"Brito","year":"2021","journal-title":"Theranostics."},{"key":"2025121109350930000_53.Supplement_1.92S.10","doi-asserted-by":"crossref","first-page":"e220157","DOI":"10.1148\/rycan.220157","article-title":"A review of theranostics: perspectives on emerging approaches and clinical advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol Imaging Cancer."},{"key":"2025121109350930000_53.Supplement_1.92S.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2012.01.002"},{"key":"2025121109350930000_53.Supplement_1.92S.12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/ntno.64141","article-title":"Radiotheranostics\u2014precision medicine in nuclear medicine and molecular imaging","volume":"6","author":"Duan","year":"2022","journal-title":"Nanotheranostics."},{"key":"2025121109350930000_53.Supplement_1.92S.13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00259-018-4204-z","article-title":"Why should we be concerned about a \u201cg\u201d?","volume":"46","author":"Frangos","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.14","doi-asserted-by":"publisher","DOI":"10.1148\/rg.266065168"},{"key":"2025121109350930000_53.Supplement_1.92S.15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jamia\/ocx152","article-title":"Expanding a radiology lexicon using contextual patterns in radiology reports","volume":"25","author":"Percha","year":"2018","journal-title":"J Am Med Inform Assoc."},{"key":"2025121109350930000_53.Supplement_1.92S.16","first-page":"242165","article-title":"Identifying nuclear medicine terms for inclusion in a nuclear medicine-specific ontology (NucLex) [abstract]","volume":"65","author":"Bradshaw","year":"2024","journal-title":"J Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269215"},{"key":"2025121109350930000_53.Supplement_1.92S.18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clon.2020.10.020","article-title":"Peptide receptor radionuclide therapy\u2014prospects for personalised treatment","volume":"33","author":"Sundl\u00f6v","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2025121109350930000_53.Supplement_1.92S.19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.semnuclmed.2025.01.005","article-title":"Potential for technetium and rhenium theranostics","volume":"55","author":"Currie","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.20","doi-asserted-by":"crossref","unstructured":"Bailey DL . Theranostics today: looking backwards to tomorrow. In: Borras C Stabin MG , eds. Radiotheranostics\u2014A Primer for Medical Physicists I: Physics, Chemistry, Biology and Clinical Applications. CRC Press; 2024:198\u2013207.","DOI":"10.1201\/9781003250913-19"},{"key":"2025121109350930000_53.Supplement_1.92S.21","doi-asserted-by":"crossref","unstructured":"Blower JE Cooper MS Imberti C . The radiopharmaceutical chemistry of radionuclides gallium and indium. In: Lewis JS Windhorst AD Zeglis BM , eds. Radiopharmaceutical Chemistry. Springer; 2019.","DOI":"10.1007\/978-3-319-98947-1_14"},{"key":"2025121109350930000_53.Supplement_1.92S.22","doi-asserted-by":"crossref","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","article-title":"Theranostic nuclear medicine with gallium-68, lutetium-177, copper-64\/67, actinium-225, and lead-212\/203 radionuclides","volume":"123","author":"Morgan","year":"2023","journal-title":"Chem Rev."},{"key":"2025121109350930000_53.Supplement_1.92S.23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41824-024-00217-5","article-title":"[18F]AlF-PSMA-11 PET in diagnosing prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-11 PET and an exploration of dual-phase scanning","volume":"8","author":"Li","year":"2024","journal-title":"EJNMMI Rep."},{"key":"2025121109350930000_53.Supplement_1.92S.24","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.7150\/thno.94788","article-title":"Theranostics and artificial intelligence: new frontiers in personalized medicine","volume":"14","author":"Belge Bilgin","year":"2024","journal-title":"Theranostics."},{"key":"2025121109350930000_53.Supplement_1.92S.25","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025121109350930000_53.Supplement_1.92S.26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","article-title":"Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer","volume":"14","author":"Ling","year":"2022","journal-title":"Pharmaceutics."},{"key":"2025121109350930000_53.Supplement_1.92S.27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2025121109350930000_53.Supplement_1.92S.28","first-page":"163","article-title":"The current status of the production and supply of gallium-68","volume":"35","author":"Kumar","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"2025121109350930000_53.Supplement_1.92S.29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5005\/jp-journals-10028-1053","article-title":"An increasing role for 68Ga PET imaging: a perspective on the availability of parent 68Ge material for generator manufacturing in an expanding market","volume":"47","author":"Schultz","year":"2013","journal-title":"J Postgrad Med Edu Res."},{"key":"2025121109350930000_53.Supplement_1.92S.30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s41824-024-00226-4","article-title":"Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry","volume":"8","author":"Tually","year":"2024","journal-title":"EJNMMI Rep."},{"key":"2025121109350930000_53.Supplement_1.92S.31","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology."},{"key":"2025121109350930000_53.Supplement_1.92S.32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.semnuclmed.2022.10.007","article-title":"Radiation dosimetry, artificial intelligence and digital twins: old dog, new tricks","volume":"53","author":"Currie","year":"2023","journal-title":"Semin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.33","doi-asserted-by":"crossref","first-page":"108337","DOI":"10.1016\/j.nucmedbio.2023.108337","article-title":"The emerging role of artificial intelligence and digital twins in pre-clinical molecular imaging","volume":"120\u2013121","author":"Currie","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2025121109350930000_53.Supplement_1.92S.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2025121109350930000_53.Supplement_1.92S.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.230607"},{"key":"2025121109350930000_53.Supplement_1.92S.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262305"},{"key":"2025121109350930000_53.Supplement_1.92S.37","doi-asserted-by":"crossref","first-page":"481279","DOI":"10.1155\/2015\/481279","article-title":"Theranostic imaging of yttrium-90","volume":"2015","author":"Wright","year":"2015","journal-title":"Biomed Res Int."},{"key":"2025121109350930000_53.Supplement_1.92S.38","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s00259-023-06252-x","article-title":"The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry","volume":"50","author":"Akhavanallaf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.39","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2967\/jnumed.118.225599","article-title":"Dual-time-point 18F-fluorocholine PET\/CT in parathyroid imaging","volume":"60","author":"Broos","year":"2019","journal-title":"J Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.40","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/RLU.0000000000003904","article-title":"Dual-time-point 18F-fluorocholine PET\/CT improves characterization of thyroid nodules in patients referred for primary hyperparathyroidism: a proof of concept study","volume":"46","author":"Bani","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MNM.0b013e32835710d6","article-title":"Potential value of dual-time-point 18F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: a systematic review and meta-analysis","volume":"33","author":"Lin","year":"2012","journal-title":"Nucl Med Commun."},{"key":"2025121109350930000_53.Supplement_1.92S.42","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/molecules23102575","article-title":"66Ga: a novelty or a valuable preclinical screening tool for the design of targeted radiopharmaceuticals?","volume":"23","author":"Amor-Coarasa","year":"2018","journal-title":"Molecules."},{"key":"2025121109350930000_53.Supplement_1.92S.43","doi-asserted-by":"crossref","first-page":"49586","DOI":"10.1039\/C7RA09076E","article-title":"Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling","volume":"7","author":"Tsionou","year":"2017","journal-title":"RSC Adv."},{"key":"2025121109350930000_53.Supplement_1.92S.44","doi-asserted-by":"crossref","unstructured":"Alva-Ensastegui JC Rivera-Mill\u00e1n R Aranda-Lara L . Lutetium coordination compounds toward potential nanoradiopharmaceutical applications: rational design and synthesis. J Mol Struct. 2024:137419.","DOI":"10.2139\/ssrn.4486808"},{"key":"2025121109350930000_53.Supplement_1.92S.45","first-page":"336","article-title":"Actinium-225 for targeted \u03b1 therapy: coordination chemistry and current chelation approaches","volume":"33","author":"Thiele","year":"2018","journal-title":"Cancer Biother Radiopharm."},{"key":"2025121109350930000_53.Supplement_1.92S.46","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/pharmaceutics15041051","article-title":"225Ac-labeled somatostatin analogs in the management of neuroendocrine tumors: from radiochemistry to clinic","volume":"15","author":"Rubira","year":"2023","journal-title":"Pharmaceutics."},{"key":"2025121109350930000_53.Supplement_1.92S.47","doi-asserted-by":"crossref","unstructured":"Marquez-Nostra BV Viola N . The radiopharmaceutical chemistry of zirconium-89. In: Lewis JS Windhorst AD Zeglis BM , eds. Radiopharmaceutical Chemistry. Springer; 2019.","DOI":"10.1007\/978-3-319-98947-1_21"},{"key":"2025121109350930000_53.Supplement_1.92S.48","first-page":"1","article-title":"RetroSPECT: gallium-67 as a long-lived imaging agent for theranostics","volume":"9","author":"Bailey","year":"2021","journal-title":"Asia Ocean J Nucl Med Biol."},{"key":"2025121109350930000_53.Supplement_1.92S.49","doi-asserted-by":"crossref","unstructured":"Currie G Rohren E . The role of artificial intelligence in theranostics. J Nucl Med Technol. 2025;53(suppl 1):82S\u201391S.","DOI":"10.2967\/jnmt.125.270251"},{"key":"2025121109350930000_53.Supplement_1.92S.50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1071\/CH21184","article-title":"The evolving coordination chemistry of radiometals for targeted alpha therapy","volume":"75","author":"Grieve","year":"2022","journal-title":"Aust J Chem."},{"key":"2025121109350930000_53.Supplement_1.92S.51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40291-024-00702-4","article-title":"Advances in radioligand theranostics in oncology","volume":"28","author":"Lawal","year":"2024","journal-title":"Mol Diagn Ther."},{"key":"2025121109350930000_53.Supplement_1.92S.52","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1007\/s00259-022-05826-5","article-title":"225Ac-DOTATATE therapy in a case of metastatic pheochromocytoma","volume":"49","author":"Peng","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.53","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.54","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1097\/RLU.0000000000003823","article-title":"Alpha before beta: exceptional response to first-line 225Ac-DOTATATE in a patient of metastatic neuroendocrine tumor with extensive skeletal involvement","volume":"47","author":"Satapathy","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.55","first-page":"101","article-title":"First successful in-human application of 225Ac-DOTA-LM3 mono-PRRT for the treatment of an otherwise therapy-resistant neuroendocrine tumor (NET G3)","volume":"50","author":"Speicher","year":"2025","journal-title":"Clin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.56","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00259-021-05512-y","article-title":"A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE","volume":"49","author":"Zhu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.57","doi-asserted-by":"crossref","first-page":"e233408","DOI":"10.1148\/radiol.233408","article-title":"Dotatate PET\/CT and 225Ac-Dotatate therapy for somatostatin receptor-expressing metastatic breast cancer","volume":"312","author":"Ulaner","year":"2024","journal-title":"Radiology."},{"key":"2025121109350930000_53.Supplement_1.92S.58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025121109350930000_53.Supplement_1.92S.59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40291-024-00699-w","article-title":"Lutetium-177 labelled anti-PSMA monoclonal antibody (Lu-TLX591) therapy for metastatic prostate cancer: treatment toxicity and outcomes","volume":"28","author":"Nguyen","year":"2024","journal-title":"Mol Diagn Ther."},{"key":"2025121109350930000_53.Supplement_1.92S.60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol."},{"key":"2025121109350930000_53.Supplement_1.92S.61","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262671"},{"key":"2025121109350930000_53.Supplement_1.92S.62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000003493","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"J Urol."},{"key":"2025121109350930000_53.Supplement_1.92S.63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/ph14070701","article-title":"Recent advances in the clinical translation of silicon fluoride acceptor (SiFA) 18F-radiopharmaceuticals","volume":"14","author":"Gower-Fry","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2025121109350930000_53.Supplement_1.92S.64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s13139-023-00804-7","article-title":"161Tb-PSMA unleashed: a promising new player in the theranostics of prostate cancer","volume":"57","author":"Al-Ibraheem","year":"2023","journal-title":"Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.65","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.66","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267650"},{"key":"2025121109350930000_53.Supplement_1.92S.67","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025121109350930000_53.Supplement_1.92S.68","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267547"},{"key":"2025121109350930000_53.Supplement_1.92S.69","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268258"},{"key":"2025121109350930000_53.Supplement_1.92S.70","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.71","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as theranostic target in oncology","volume":"22","author":"Bocuzzi","year":"2024","journal-title":"J Transl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.72","first-page":"100465","article-title":"Prioritising breast cancer theranostics: a current medical longing in oncology","volume":"29","author":"Pandey","year":"2021","journal-title":"Cancer Treat Res Commun."},{"key":"2025121109350930000_53.Supplement_1.92S.73","first-page":"817","article-title":"The role of theragnostics in breast cancer: a systematic review of the last 12 years","volume":"19","author":"Balma","year":"2023","journal-title":"Curr Med Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.74","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","article-title":"Theranostic approach in breast cancer: a treasured tailor for future oncology","volume":"46","author":"Jokar","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cpet.2021.03.011","article-title":"An impressive approach in nuclear medicine: theranostics","volume":"16","author":"Vahidfar","year":"2021","journal-title":"PET Clin."},{"key":"2025121109350930000_53.Supplement_1.92S.76","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268325"},{"key":"2025121109350930000_53.Supplement_1.92S.77","first-page":"332","article-title":"Head to head comparison performance of 99mTc-EDDA\/HYNIC-iPSMA SPECT\/CT and 68Ga-PSMA-11 PET\/CT a prospective study in biochemical recurrence prostate cancer patients","volume":"8","author":"Garc\u00eda-P\u00e9rez","year":"2018","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.78","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pros.23379","article-title":"Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET\/CT","volume":"77","author":"Lawal","year":"2017","journal-title":"Prostate."},{"key":"2025121109350930000_53.Supplement_1.92S.79","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.semnuclmed.2023.11.005","article-title":"SPECT\/CT, PET\/CT, and PET\/MRI for response assessment of bone metastases","volume":"54","author":"Zamani-Siahkali","year":"2024","journal-title":"Semin Nucl Med."},{"key":"2025121109350930000_53.Supplement_1.92S.80","unstructured":"Duatto A . Fundamentals of technetium and rhenium chemistry. In: Theobald T ed. Sampson\u2019s Textbook of Radiopharmacy. 4th ed. Pharmaceutical Press; 2011:101\u2013124."},{"key":"2025121109350930000_53.Supplement_1.92S.81","unstructured":"Kowalsky RJ Falen SW . Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. 2nd ed. American Pharmacists Association; 2004:235\u2013336."},{"key":"2025121109350930000_53.Supplement_1.92S.82","doi-asserted-by":"crossref","unstructured":"Boschi A Uccelli L Pasquali M . 188W\/188Re generator system and its therapeutic applications. J Chem. 2014;529406.","DOI":"10.1155\/2014\/529406"},{"key":"2025121109350930000_53.Supplement_1.92S.83","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s13139-024-00866-1","article-title":"Optimized production of 188Re-HYNIC-bombesin: new therapeutic agent for GRPR targeting","volume":"58","author":"Vosoughi","year":"2024","journal-title":"Nucl Med Mol Imaging."},{"key":"2025121109350930000_53.Supplement_1.92S.84","first-page":"188","article-title":"Unraveling interaction of rhenium-188 microspheres with primary hepatic cancer cell: a breakthrough study","volume":"39","author":"Aggarwal","year":"2024","journal-title":"Cancer Biother Radiopharm."},{"key":"2025121109350930000_53.Supplement_1.92S.85","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1874471011205030228","article-title":"Rhenium-188: availability from the 188W\/188Re generator and status of current applications","volume":"5","author":"Pillai","year":"2012","journal-title":"Curr Radiopharm."},{"key":"2025121109350930000_53.Supplement_1.92S.86","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front Med (Lausanne)."},{"key":"2025121109350930000_53.Supplement_1.92S.87","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265199"},{"key":"2025121109350930000_53.Supplement_1.92S.88","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.239731"},{"key":"2025121109350930000_53.Supplement_1.92S.89","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267450"},{"key":"2025121109350930000_53.Supplement_1.92S.90","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264944"},{"key":"2025121109350930000_53.Supplement_1.92S.91","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186866"},{"key":"2025121109350930000_53.Supplement_1.92S.92","unstructured":"Currie G . Theranostics. In: Gilmore D Wasterstram-Rich KM , eds. Nuclear Medicine and Molecular Imaging: Technology and Techniques. 9th ed. Elsevier; 2022."},{"key":"2025121109350930000_53.Supplement_1.92S.93","doi-asserted-by":"crossref","first-page":"e1078","DOI":"10.52225\/narra.v4i3.1078","article-title":"Exploring the promising therapeutic benefits of iodine and radioiodine in breast cancer cell lines","volume":"4","author":"Elliyanti","year":"2024","journal-title":"Narra J."}],"container-title":["Journal of Nuclear Medicine Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnmt.125.270169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:36:09Z","timestamp":1765474569000},"score":1,"resource":{"primary":{"URL":"http:\/\/tech.snmjournals.org\/lookup\/doi\/10.2967\/jnmt.125.270169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":93,"journal-issue":{"issue":"Supplement 1","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.2967\/jnmt.125.270169"],"URL":"https:\/\/doi.org\/10.2967\/jnmt.125.270169","relation":{},"ISSN":["0091-4916","1535-5675"],"issn-type":[{"value":"0091-4916","type":"print"},{"value":"1535-5675","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}